keyword
MENU ▼
Read by QxMD icon Read
search

Cell free circulating cancer DNA

keyword
https://www.readbyqxmd.com/read/29144792/effect-of-blood-collection-tube-type-and-time-to-processing-on-the-enumeration-and-high-content-characterization-of-circulating-tumor-cells-using-the-high-definition-single-cell-assay
#1
Mariam Rodríguez-Lee, Anand Kolatkar, Madelyn McCormick, Angel D Dago, Jude Kendall, Nils Anders Carlsson, Kelly Bethel, Emily J Greenspan, Shelley E Hwang, Kathryn R Waitman, Jorge J Nieva, James Hicks, Peter Kuhn
CONTEXT: - As circulating tumor cell (CTC) assays gain clinical relevance, it is essential to address preanalytic variability and to develop standard operating procedures for sample handling in order to successfully implement genomically informed, precision health care. OBJECTIVE: - To evaluate the effects of blood collection tube (BCT) type and time-to-assay (TTA) on the enumeration and high-content characterization of CTCs by using the high-definition single-cell assay (HD-SCA)...
November 16, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/29138500/circulating-androgen-receptor-combined-with-18f-fluorocholine-pet-ct-metabolic-activity-and-outcome-to-androgen-receptor-signalling-directed-therapies-in-castration-resistant-prostate-cancer
#2
V Conteduca, E Scarpi, P Caroli, S Salvi, C Lolli, S L Burgio, C Menna, G Schepisi, S Testoni, G Gurioli, G Paganelli, V Casadio, F Matteucci, U De Giorgi
The association between choline uptake and androgen receptor (AR) expression is suggested by the upregulation of choline kinase-alpha in prostate cancer. Recently, detection of AR aberration in cell-free DNA as well as early 18F-fluorocholine positron emission tomography/computed tomography (FCH-PET/CT) were associated with outcome in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone and enzalutamide. We aimed to make a direct comparison between circulating AR copy number (CN) and choline uptake at FCH-PET/CT...
November 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29137355/a-pilot-study-evaluating-concordance-between-blood-based-and-patient-matched-tumor-molecular-testing-within-pancreatic-cancer-patients-participating-in-the-know-your-tumor-kyt-initiative
#3
Michael J Pishvaian, R Joseph Bender, Lynn M Matrisian, Lola Rahib, Andrew Hendifar, William A Hoos, Sam Mikhail, Vincent Chung, Vincent Picozzi, Craig Heartwell, Kimberly Mason, Katelyn Varieur, Metasebia Aberra, Subha Madhavan, Emanuel Petricoin, Jonathan R Brody
Recent improvements in next-generation sequencing (NGS) technology have enabled detection of biomarkers in cell-free DNA in blood and may ultimately replace invasive tissue biopsies. However, a better understanding of the performance of blood-based NGS assays is needed prior to routine clinical use. As part of an IRB-approved molecular profiling registry trial of pancreatic ductal adenocarcinoma (PDA) patients, we facilitated blood-based NGS testing of 34 patients from multiple community-based and high-volume academic oncology practices...
October 13, 2017: Oncotarget
https://www.readbyqxmd.com/read/29136733/-exploratory-study-of-circulating-tumor-dna-detection-in-early-breast-cancer-an-analysis-of-75-next-generation-sequencing-results
#4
B Zhou, L Xin, L Xu, Y H Liu, M M Zhang, R L Jing, X Y Liang, S B Cao
Objective: To explore the utility of circulating tumor DNA detection in early breast cancer by using next-generation sequencing. Methods: This exploratory study of circulating tumor DNA detection is for early invasive breast cancer patients treated in Breast Disease Center, Peking University First Hospital from December 2015 to July 2016. Plasma samples were collected and were used to isolate plasma cell-free DNA.Exons or hotspots of 247 cancer related genes were sequenced by next-generation sequencing. Mutations and their correlation with clinic-pathological factors were analyzed...
November 1, 2017: Zhonghua Wai Ke za Zhi [Chinese Journal of Surgery]
https://www.readbyqxmd.com/read/29132396/circulating-cell-free-dna-and-circulating-tumor-cells-the-liquid-biopsies-in-ovarian-cancer
#5
REVIEW
Xianliang Cheng, Lei Zhang, Yajuan Chen, Chen Qing
Limited understanding of ovarian cancer (OC) genome portrait has hindered the therapeutic advances. The serial monitoring of tumor genotypes is becoming increasingly attainable with circulating cell-free DNA (cf-DNA) and circulating tumor cells (CTCs) emerging as "liquid biopsies". They represent non-invasive biomarkers and are viable, as they can be isolated from human plasma, serum and other body fluids. Molecular characterization of circulating tumor DNA (ct-DNA) and CTCs offer unique potentials to better understand the biology of metastasis and resistance to therapies...
November 13, 2017: Journal of Ovarian Research
https://www.readbyqxmd.com/read/29130594/dna-damage-and-circulating-cell-free-dna-in-greenhouse-workers-exposed-to-pesticides
#6
Akin Çayir, Mahmut Coskun, Munevver Coskun, Hayal Cobanoglu
Pesticides widely used in agriculture and other applications have been linked to cancer and other diseases through several potential mechanisms. The goals of this study were to assess DNA damage in lymphocytes by the cytokinesis-block micronucleus assay (CBMN), and to measure circulating cell free DNA (ccf-DNA) in the blood of pesticide-exposed greenhouse workers and matched controls living in the same area. CBMN was applied to peripheral blood lymphocyte samples taken at different times (spring and autumn) for each individual...
November 11, 2017: Environmental and Molecular Mutagenesis
https://www.readbyqxmd.com/read/29113658/circulating-cell-free-dna-in-plasma-of-colorectal-cancer-patients-a-potential-biomarker-for-tumor-burden
#7
Jagdeep Singh Bhangu, Hossein Taghizadeh, Tamara Braunschmid, Thomas Bachleitner-Hofmann, Christine Mannhalter
BACKGROUND: Measurement of cell-free DNA (cfDNA) in plasma - the so called liquid biopsy - is a novel method for early detection of cancer. Necrotic cancer cells release various DNA fragments that can be detected in plasma or serum. The aim of our study was to investigate the concentration of circulating ALU115, LINE79 and LINE297 fragments in plasma from venous and arterial blood of colorectal cancer (CRC) patients before, during and 5 days after surgical intervention. PATIENTS AND METHODS: Thirty patients (16 female, 14 male, median age 56 years), undergoing surgery for colorectal and appendix cancer, and 17 healthy volunteers were included in this study...
December 2017: Surgical Oncology
https://www.readbyqxmd.com/read/29110846/egfr-mutation-prevalence-in-asia-pacific-and-russian-patients-with-advanced-nsclc-of-adenocarcinoma-and-non-adenocarcinoma-histology-the-ignite-study
#8
Baohui Han, Sergei Tjulandin, Koichi Hagiwara, Nicola Normanno, Laksmi Wulandari, Konstantin Laktionov, Achmad Hudoyo, Yong He, Yi-Ping Zhang, Meng-Zhao Wang, Chien Ying Liu, Marianne Ratcliffe, Rose McCormack, Martin Reck
OBJECTIVES: Limited understanding exists of epidermal growth factor receptor (EGFR) mutation frequency in less common subgroups of advanced non-small-cell lung cancer (aNSCLC) (e.g. squamous cell carcinoma [SCC]), and to what extent local practices exclude patients from EGFR testing based on their clinical characteristics. MATERIALS AND METHODS: IGNITE (non-comparative/-interventional; NCT01788163) was conducted in 90 centres (Asia-Pacific/Russia). Eligible patients: local/metastatic aNSCLC; chemotherapy-naïve, newly-diagnosed/recurrent disease after resection; ineligible for curative treatment...
November 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29108273/sensitive-droplet-digital-pcr-method-for-detection-of-tert-promoter-mutations-in-cell-free-dna-from-patients-with-metastatic-melanoma
#9
Ashleigh C McEvoy, Leslie Calapre, Michelle R Pereira, Tindaro Giardina, Cleo Robinson, Muhammad A Khattak, Tarek M Meniawy, Antonia L Pritchard, Nicholas K Hayward, Benhur Amanuel, Michael Millward, Melanie Ziman, Elin S Gray
Background: Currently mainly BRAF mutant circulating tumor DNA (ctDNA) is utilized to monitor patients with melanoma. TERT promoter mutations are common in various cancers and found in up to 70% of melanomas, including half of BRAF wild-type cases. Therefore, a sensitive method for detection of TERT promoter mutations would increase the number of patients that could be monitored through ctDNA analysis. Methods: A droplet digital PCR (ddPCR) assay was designed for the concurrent detection of chr5:1,295,228 C>T and chr5:1,295,250 C>T TERT promoter mutations...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29072129/cell-free-mitochondrial-dna-copy-number-variation-in-head-and-neck-squamous-cell-carcinoma-a-study-of-non-invasive-biomarker-from-northeast-india
#10
Manish Kumar, Shilpee Srivastava, Seram Anil Singh, Anup Kumar Das, Ganesh Chandra Das, Bishal Dhar, Sankar Kumar Ghosh, Rosy Mondal
Head and neck squamous cell carcinoma is the most commonly diagnosed cancer worldwide. The lifestyle, food habits, and customary practices manifest the Northeast Indian population toward higher susceptibility to develop head and neck squamous cell carcinoma. Here, we have investigated the association of smoke and smokeless tobacco, and alcohol with copy number variation of cell-free mitochondrial DNA and cell-free nuclear DNA in cases and controls. Cell-free DNA from plasma was isolated from 50 head and neck squamous cell carcinoma cases and 50 controls with informed written consent using QIAamp Circulating Nucleic Acid Kit...
October 2017: Tumour Biology: the Journal of the International Society for Oncodevelopmental Biology and Medicine
https://www.readbyqxmd.com/read/29069959/the-liquid-biopsy-a-tool-for-a-combined-diagnostic-and-theranostic-approach-for-care-of-a-patient-with-late-stage-lung-carcinoma-presenting-with-bilateral-ocular-metastases
#11
Linda Bouhlel, Véronique Hofman, Célia Maschi, Marius Ilié, Maryline Allégra, Charles-Hugo Marquette, Clarisse Audigier-Valette, Juliette Thariat, Paul Hofman
Liquid biopsies (LB) are used routinely in clinical practice in two situations for late stage non-small-cell lung cancer (NSCLC) patients, (i) at the initial diagnosis when looking for activating mutations in EGFR in the absence of analyzable tissue DNA and, (ii) during tumor progression on a tyrosine kinase inhibitor treatment to look for the resistance mutation T790M in EGFR. LB is not presently recommended in daily practice for the diagnosis of NSCLC. Areas covered: We report the diagnosis of a NSCLC in a patient with bilateral ocular metastases after detection of a deletion in exon 19 of EGFR when using plasma DNA...
November 2, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/29067441/multiplex-picoliter-droplet-digital-pcr-for-quantitative-assessment-of-egfr-mutations-in-circulating-cell-free-dna-derived-from-advanced-non-small-cell-lung-cancer-patients
#12
Qian Yu, Fei Huang, Meilin Zhang, Haiying Ji, Shenchao Wu, Ying Zhao, Chunyan Zhang, Jiong Wu, Beili Wang, Baisheng Pan, Xin Zhang, Wei Guo
To explore the possible diagnostic value of liquid biopsy, two multiplex panels using picoliter-droplet digital polymerase chain reaction (ddPCR) were established to quantitatively assess the epidermal growth factor receptor (EGFR) mutations in cell‑free DNA (cfDNA) extracted from the plasma of advanced non‑small cell lung cancer (NSCLC) patients. Plasma samples derived from 22 patients with stage IIIB/IV NSCLC harboring EGFR mutations in matched tumor tissues confirmed by amplification refractory mutation system (ARMS) analysis were subjected to two multiplex ddPCR panels to assess the abundance of tyrosine kinase inhibitor (TKI) ‑sensitive (19DEL, L858R) and TKI‑resistant (T790 M) mutations...
August 2017: Molecular Medicine Reports
https://www.readbyqxmd.com/read/29066904/review-of-the-clinical-applications-and-technological-advances-of-circulating-tumor-dna-in-cancer-monitoring
#13
REVIEW
Yi Chang, Bhairavi Tolani, Xiuhong Nie, Xiuyi Zhi, Mu Hu, Biao He
Circulating cell-free DNA (cfDNA) released by tumor cells, termed ctDNA, closely reflects the heterogeneity of primary cancers and their metastases. As a noninvasive, real-time monitoring biomarker, ctDNA is a promising tool for detecting driver gene mutations, assessing tumor burden and acquired resistance, and early diagnosis. However, isolation and enrichment of cfDNA is a big challenge due to the high degree of DNA fragmentation and its relatively low abundance in the bloodstream. This review aims to provide insights into the recent technological advances in acquisition of optimal quality cfDNA, the use of preservatives, isolation methods, processing timelines, and detection techniques...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29063719/aberrant-single-minded-homolog-1-methylation-as-a-potential-biomarker-for-cervical-cancer
#14
Hyun-Jung Kim, Chan Young Kim, Jinghui Jin, Moon Kyoung Bae, Yun Hee Kim, Woong Ju, Yun Hwan Kim, Seung Cheol Kim
BACKGROUND: The aim of this study is to evaluate the possibility of using the methylation status of single-minded homolog 1 (SIM1) as a diagnostic biomarker for cervical cancer. METHODS: All the patient and normal specimens including the normal cervix (n = 10), cervical cancer tissues (n = 45), blood (n = 45), and cervical brush specimens (n = 110) were retrospectively obtained. Quantitative methylation-specific PCR was performed to detect SIM1 methylation in primary tumors, cervical brush specimens, and plasma circulating cell-free DNA (ccfDNA)...
October 24, 2017: Diagnostic Cytopathology
https://www.readbyqxmd.com/read/29063679/estrogen-receptor-mutations-and-splice-variants-determined-in-liquid-biopsies-from-metastatic-breast-cancer-patients
#15
Nick Beije, Anieta M Sieuwerts, Jaco Kraan, Ngoc M Van, Onstenk Wendy, Silvia R Vitale, Michelle van der Vlugt-Daane, Luc Y Dirix, Anja Brouwer, Paul Hamberg, Felix E de Jongh, Agnes Jager, Caroline M Seynaeve, Maurice P H M Jansen, John A Foekens, John W M Martens, Stefan Sleijfer
Mutations and splice variants in the estrogen receptor (ER) gene, ESR1, may yield endocrine resistance in metastatic breast cancer (MBC) patients. These putative endocrine resistance markers are likely to emerge during treatment and therefore its detection in liquid biopsies, such as circulating tumor cells (CTCs) and cell-free DNA (cfDNA), is of great interest. This research aimed to determine if ESR1 mutations and splice variants occur more frequently in CTCs of MBC patients progressing on endocrine treatment...
October 24, 2017: Molecular Oncology
https://www.readbyqxmd.com/read/29061138/the-evidence-base-for-circulating-tumour-dna-blood-based-biomarkers-for-the-early-detection-of-cancer-a-systematic-mapping-review
#16
Ian A Cree, Lesley Uttley, Helen Buckley Woods, Hugh Kikuchi, Anne Reiman, Susan Harnan, Becky L Whiteman, Sian Taylor Philips, Michael Messenger, Angela Cox, Dawn Teare, Orla Sheils, Jacqui Shaw
BACKGROUND: The presence of circulating cell-free DNA from tumours in blood (ctDNA) is of major importance to those interested in early cancer detection, as well as to those wishing to monitor tumour progression or diagnose the presence of activating mutations to guide treatment. In 2014, the UK Early Cancer Detection Consortium undertook a systematic mapping review of the literature to identify blood-based biomarkers with potential for the development of a non-invasive blood test for cancer screening, and which identified this as a major area of interest...
October 23, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29035458/concordance-of-mutation-detection-in-circulating-tumor-dna-in-early-clinical-trials-using-different-blood-collection-protocols
#17
Lise B Ahlborn, Mette Madsen, Lars Jonson, Finn C Nielsen, Ulrik Lassen, Christina W Yde, Morten Mau-Sorensen
BACKGROUND: Small fragments of tumor DNA can be found in the circulation of cancer patients, providing a noninvasive access to tumor material (liquid biopsy). Analysis of circulating tumor DNA (ctDNA) has been used for diagnosis, treatment decisions, and detection of therapy resistance, including in patients with tumors inaccessible for biopsy, making ctDNA an important alternative source of tumor material. Immediate separation of plasma is widely used in standard isolation of cell-free DNA to ensure high quality plasma DNA...
October 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/28993799/genetic-characterization-of-brain-metastases-in-the-era-of-targeted-therapy
#18
REVIEW
Catherine H Han, Priscilla K Brastianos
In the current era of molecularly targeted therapies and precision medicine, choice of cancer treatment has been increasingly tailored according to the molecular or genomic characterization of the cancer the individual has. Previously, the clinical observation of inadequate control of brain metastases was widely attributed to a lack of central nervous system (CNS) penetration of the anticancer drugs. However, more recent data have suggested that there are genetic explanations for such observations. Genomic analyses of brain metastases and matching primary tumor and other extracranial metastases have revealed that brain metastases can harbor potentially actionable driver mutations that are unique to them...
2017: Frontiers in Oncology
https://www.readbyqxmd.com/read/28990755/tunable-and-linker-free-nanogaps-in-core-shell-plasmonic-nanorods-for-selective-and-quantitative-detection-of-circulating-tumor-cells-by-sers
#19
Yang Zhang, Peng Yang, Madathumpady Abubaker Habeeb Muhammed, Shahad K Alsaiari, Basem Moosa, Abdulaziz Almalik, Anjli Kumar, Emilie Ringe, Niveen M Khashab
Controlling the size, number, and shape of nanogaps in plasmonic nanostructures is of significant importance for the development of novel quantum plasmonic devices and quantitative sensing techniques such as surface-enhanced Raman scattering (SERS). Here, we introduce a new synthetic method based on coordination interactions and galvanic replacement to prepare core-shell plasmonic nanorods with tunable enclosed nanogaps. Decorating Au nanorods with Raman reporters that strongly coordinate Ag(+) ions (e.g., 4-mercaptopyridine) afforded uniform nucleation sites to form a sacrificial Ag shell...
October 18, 2017: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/28982739/discovery-of-methylated-circulating-dna-biomarkers-for-comprehensive-non-invasive-monitoring-of-treatment-response-in-metastatic-colorectal-cancer
#20
Ludovic Barault, Alessio Amatu, Giulia Siravegna, Agostino Ponzetti, Sebastian Moran, Andrea Cassingena, Benedetta Mussolin, Chiara Falcomatà, Alexandra M Binder, Carmen Cristiano, Daniele Oddo, Simonetta Guarrera, Carlotta Cancelliere, Sara Bustreo, Katia Bencardino, Sean Maden, Alice Vanzati, Patrizia Zavattari, Giuseppe Matullo, Mauro Truini, William M Grady, Patrizia Racca, Karin B Michels, Salvatore Siena, Manel Esteller, Alberto Bardelli, Andrea Sartore-Bianchi, Federica Di Nicolantonio
OBJECTIVE: Mutations in cell-free circulating DNA (cfDNA) have been studied for tracking disease relapse in colorectal cancer (CRC). This approach requires personalised assay design due to the lack of universally mutated genes. In contrast, early methylation alterations are restricted to defined genomic loci allowing comprehensive assay design for population studies. Our objective was to identify cancer-specific methylated biomarkers which could be measured longitudinally in cfDNA (liquid biopsy) to monitor therapeutic outcome in patients with metastatic CRC (mCRC)...
October 5, 2017: Gut
keyword
keyword
100266
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"